
UK SMEs are using ‘in silico’ technologies to support a range of exciting outcomes in the life sciences and medical technology sectors. These include improving and accelerating our ability to tackle disease and health problems with more effective treatments, drugs and medical devices.
In silico refers to the use of computer modelling and simulation to undertake virtual experiments.
Over the last decade, in silico SMEs in the UK have received a total of £860m worth of equity investment. Most funding rounds have been secured by companies at the venture or seed stage, reflecting the relative youth of the sector.
This investment, alongside university and corporate support, is key to the ongoing development of in silico technologies, and the UK is well placed to become a global leader in this space.
Click here to read our analysis of the UK’s private in silico sector, including demographic data and investment trends.Inside the report…


About the authors
More leads, more clients, less churn.
Get access to unrivalled data on all the companies you need to know about, so you can approach the right leads, at the right time.
Book a demo today to see all of the key features, as well as the depth and breadth of data available on the Beauhurst platform.
An associate will work with you to build a sophisticated search, returning a dynamic list of organisations matching your ideal client profile.




